- Thursday 11th December
- 13:00 – 15:00 (BRT)
- This webinar was delivered entirely in Portuguese.
Are you looking to strengthen your understanding of the ICH M7(R2) guideline and learn practical approaches to conducting compliant impurity risk assessments?
This live webinar, delivered fully in Portuguese, explored how the ICH M7 framework supports the assessment and control of DNA-reactive (mutagenic) impurities in pharmaceuticals, helping to limit potential carcinogenic risk.
Our speakers discussed how to apply ICH M7 principles in practice using Lhasa Limited expert knowledge-based and statistical in silico tools, Derek Nexus and Sarah Nexus, to support scientifically robust and defensible impurity assessments.
In addition, an industry toxicologist presented on how ICH M7 principles are being implemented in real-world scenarios.
Meet the speakers
- Roberta Drekener, Senior Application Scientist, Lhasa Limited
- Karen Rafaela Gonçalves de Araújo, Development Analyst, Libbs Farmacêutica
- Valéria Vassiliades, Project Coordinator and Researcher, Spektra Consultoria
Why catch up on the recording?
- Gain a clear understanding of ICH M7(R2) and its impact on pharmaceutical impurity management.
- See how in silico tools can enhance the efficiency and scientific defensibility of your risk assessments.
- Learn from Brazilian experts already applying ICH M7 principles in practice.